SCHEMBL5871849

SCHEMBL5871849

OCC1CN(Cc2ccccc2)CCC12OCCO2

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 5/20 0.46
TMEM97 Q5BJF2 1/20 0.45
OPRL1 P41146 1/20 0.44
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 2/20 0.43
TSHR P16473 2/20 0.43
KMT2A Q03164 2/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
HIF1A Q16665 1/20 0.43
POLB P06746 1/20 0.43
CYP3A4 P08684 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP2D6 P10635 1/20 0.43
DRD4 P21917 1/20 0.43
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
MAPK1 P28482 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15720969 0.81 OPRM1 (0.49) SIGMAR1TMEM97OPRL1ALDH1A1MEN1
SCHEMBL173992 0.80 ALDH1A1 (0.53) SIGMAR1TMEM97OPRL1ALDH1A1MEN1
SCHEMBL21483087 0.79 ALDH1A1 (0.48) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL21209747 0.79 OPRL1 (0.51) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL12490905 0.79 ALDH1A1 (0.48) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL21462564 0.79 ALDH1A1 (0.48) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL6331329 0.78 ALDH1A1 (0.49) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL31516385 0.75 OPRL1 (0.50) SIGMAR1OPRL1ALDH1A1MEN1TSHR
SCHEMBL170770 0.73 SIGMAR1 (0.53) SIGMAR1ALDH1A1MEN1KMT2ACYP2C9
SCHEMBL23717618 0.73 CYP2D6 (0.49) SIGMAR1ALDH1A1MEN1TSHRKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7071201-B2 Serotonin antagonism; muscle relaxant for myotonia; such as 1-(1-(2-(4-methoxyphenyl)ethyl)piperidin-4-yl)-7-methoxy-1,2,3,4 -tetrahydroquinoline EISAI CO., LTD. (JP) 2006-07-04 US disclosed
EP-0976732-B1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES EISAI CO LTD (JP) 2004-11-24 EP disclosed
US-6579881-B2 Indoles EISAI CO., LTD. (JP) 2003-06-17 US disclosed
US-6448243-B1 SEROTONIN ANTAGONIST FOR TREATING, AMELIORATING AND PREVENTING SPASTIC PARALYSIS OR CENTRAL MUSCLE RELAXANTS FOR AMELIORATING MYOTONIA EISAI CO., LTD. (JP) 2002-09-10 US disclosed
US-20020086999-A1 Certain quinoline derivatives EISAI CO., LTD. 2002-07-04 US disclosed
US-20020019531-A1 Indoles EISAI CO., LTD. 2002-02-14 US disclosed
EP-0976732-A1 1,4-SUBSTITUTED CYCLIC AMINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-02-02 EP disclosed
US-5583000-A DETECTING PRESENCE OF RETROVIRAL PROTEASES IN SAMPLE BY COMBINING WITH SPECIFIED COMPOUND AND DETECTING PRESENCE OF COMPLEXES FORMED THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 1996-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019531-A1 Indoles INMT, MUSK, MB SIGMAR1 1200/4885TMEM97 4722/4885OPRL1 992/4885
US-20020086999-A1 Certain quinoline derivatives CHRM1, CHRNA5, CHRNA4 SIGMAR1 523/4885TMEM97 3592/4885OPRL1 665/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.